{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:08:23Z","timestamp":1790784503872,"version":"4.1.0"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,2,20]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib) from 1 January 2015 to 30 June 2021. The primary outcome was a serious infection (ie, requiring hospitalisation), in a time-to-event analysis using propensity score-weighted Cox models, with adalimumab as the comparator, estimating weighted HRs (wHRs) and their 95% CIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 12\u2009071 patients were included (mean age 48.7\u00b112.7 years; 6965 (57.7%) women). We identified 367 serious infections (3.0% of patients), with a crude incidence rate of 17.0 per 1000 person-years (95% CI, 15.2 to 18.7). After inverse propensity score weighting and adjustment for time-dependent covariates and calendar year, risk of serious infection was significantly lower for new users of etanercept (wHR 0.72; 95% CI, 0.53 to 0.97) or ustekinumab (wHR, 0.57; 95% CI, 0.35 to 0.93) than adalimumab new users. This risk was not statistically modified with the other targeted therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The incidence of serious infection was low for PsA patients who were new users of targeted therapies in real-world settings. Relative to adalimumab new users, this risk was lower among new users of etanercept and ustekinumab and unmodified for the other molecules.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003865","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T22:40:12Z","timestamp":1710456012000},"page":"e003865","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-8180","authenticated-orcid":false,"given":"L\u00e9a","family":"Bastard","sequence":"first","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), University Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"},{"name":"Rheumatology, Hospital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-0544","authenticated-orcid":false,"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), University Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"},{"name":"Rheumatology, Hospital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Penso","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), University Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), University Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"},{"name":"Dermatology, Hospital Henri Mondor, Cr\u00e9teil, France"},{"name":"Clinical Investigation Center 1430, INSERM, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-1148","authenticated-orcid":false,"given":"Laura","family":"Pina Vegas","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), University Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"},{"name":"Rheumatology, Hospital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2025090312484926000_10.1.e003865.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090312484926000_10.1.e003865.2","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol"},{"key":"2025090312484926000_10.1.e003865.3","unstructured":"Aletaha D , Askling J , Bae SC , et al . Annals of the rheumatic diseases publishes original work on all aspects of rheumatology and disorders of connective tissue. laboratory and clinical studies are equally welcome. 2023."},{"key":"2025090312484926000_10.1.e003865.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221007"},{"key":"2025090312484926000_10.1.e003865.5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2025090312484926000_10.1.e003865.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217092"},{"key":"2025090312484926000_10.1.e003865.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207841"},{"key":"2025090312484926000_10.1.e003865.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"2025090312484926000_10.1.e003865.9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2025090312484926000_10.1.e003865.10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-021-00388-8","article-title":"Ixekizumab demonstrates consistent efficacy versus adalimumab in biologic disease-modifying anti-rheumatic drug-Na\u00efve psoriatic arthritis patients regardless of psoriasis severity: 52-week post hoc results from SPIRIT-H2H","volume":"9","author":"Kristensen","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090312484926000_10.1.e003865.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312484926000_10.1.e003865.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"2025090312484926000_10.1.e003865.13","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1705785"},{"key":"2025090312484926000_10.1.e003865.14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025090312484926000_10.1.e003865.15","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025090312484926000_10.1.e003865.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140067"},{"key":"2025090312484926000_10.1.e003865.17","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/acr.24630","article-title":"Risk of hospitalized serious infection after initiating ustekinumab or other biologics for psoriasis or psoriatic arthritis","volume":"74","author":"Jin","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312484926000_10.1.e003865.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216102"},{"key":"2025090312484926000_10.1.e003865.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.4585"},{"key":"2025090312484926000_10.1.e003865.20","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the Syst\u00e8me national D\u2019Information Interr\u00e9gimes de L\u2019Assurance Maladie (SNIIRAM) to the Syst\u00e8me national des Donn\u00e9es de Sant\u00e9 (SNDS) in France","volume":"65 Suppl 4","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2025090312484926000_10.1.e003865.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-017-4967-3","article-title":"Ability of ecological deprivation indices to measure social inequalities in a French cohort","volume":"17","author":"Temam","year":"2017","journal-title":"BMC Public Health"},{"key":"2025090312484926000_10.1.e003865.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2021.100281","article-title":"Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative Healthcare databases (SNDS)","volume":"13","author":"Pol","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2025090312484926000_10.1.e003865.23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025090312484926000_10.1.e003865.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222824"},{"key":"2025090312484926000_10.1.e003865.25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/keaa448","article-title":"Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database","volume":"60","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312484926000_10.1.e003865.26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.respe.2021.02.002","article-title":"Algorithms to identify chronic inflammatory rheumatism and psoriasis in medico-administrative databases: a review of the literature","volume":"69","author":"Castagn\u00e9","year":"2021","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2025090312484926000_10.1.e003865.27","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"French society for rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2025090312484926000_10.1.e003865.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090312484926000_10.1.e003865.29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/pds.4006","article-title":"Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database","volume":"25","author":"Sahli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025090312484926000_10.1.e003865.30","doi-asserted-by":"crossref","unstructured":"Hardin JW . The sandwich estimate of variance. In: Advances in econometrics. Bingley: Emerald (MCB UP), 2003: 45\u201373. Available: https:\/\/www.emerald.com\/insight\/content\/doi\/10.1016\/S0731-9053(03)17003-X\/full\/html","DOI":"10.1016\/S0731-9053(03)17003-X"},{"key":"2025090312484926000_10.1.e003865.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"2025090312484926000_10.1.e003865.32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24050-7","article-title":"TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French national health data system","volume":"12","author":"Jourdain","year":"2022","journal-title":"Sci Rep"},{"key":"2025090312484926000_10.1.e003865.33","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S2589-7500(23)00025-0","article-title":"The impact of commercial health datasets on medical research and health-care algorithms","volume":"5","author":"Alberto","year":"2023","journal-title":"Lancet Digit Health"},{"key":"2025090312484926000_10.1.e003865.34","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/acr.22815","article-title":"Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review","volume":"68","author":"Desai","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312484926000_10.1.e003865.35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/14787210.2018.1544490","article-title":"Risk of infection associated with anti-TNF-\u0391 therapy","volume":"16","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025090312484926000_10.1.e003865.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.23447"},{"key":"2025090312484926000_10.1.e003865.37","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.896334"},{"key":"2025090312484926000_10.1.e003865.38","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.2.418"},{"key":"2025090312484926000_10.1.e003865.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222879"},{"key":"2025090312484926000_10.1.e003865.40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14740338.2017.1323864","article-title":"The safety of ustekinumab for the treatment of psoriatic arthritis","volume":"16","author":"L\u00f3pez-Ferrer","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2025090312484926000_10.1.e003865.41","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17815"},{"key":"2025090312484926000_10.1.e003865.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.08.054"},{"key":"2025090312484926000_10.1.e003865.43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000444581","article-title":"Patient adherence to biologic agents in psoriasis","volume":"232","author":"Hsu","year":"2016","journal-title":"Dermatology"},{"key":"2025090312484926000_10.1.e003865.44","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5705"},{"key":"2025090312484926000_10.1.e003865.45","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/sim.3854","article-title":"The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies","volume":"29","author":"Austin","year":"2010","journal-title":"Statist Med"},{"key":"2025090312484926000_10.1.e003865.46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002681","article-title":"Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)","volume":"8","author":"Pina Vegas","year":"2022","journal-title":"RMD Open"},{"key":"2025090312484926000_10.1.e003865.47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:49:03Z","timestamp":1756928943000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,14]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/rmdopen-2023-003865"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003865","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}